HMN 2025: How tirzepatide slowed obesity-associated breast cancer development

The anti-obesity treatment tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight problems, diminished obesity-associated breast cancer development in a mouse model, based on a review being offered Saturday at ENDO 2025, the Endocrine Society’s annual assembly in San Francisco, Calif.

“Obesity is a major danger issue for breast cancer, and whereas it is vitally preliminary information, our research in mice recommend that these new anti-weight problems medicine could also be a method to cut back obesity-associated breast cancer danger or enhance outcomes,” mentioned study writer Amanda Kucinskas, B.S., a Ph.D. candidate within the labs of Drs. Erin Giles and Kanakadurga Singer on the University of Michigan in Ann Arbor, Mich.

Existing analysis has proven that having weight problems can result in worse breast cancer outcomes in comparison with those that don’t have weight problems, and weight reduction can enhance outcomes. However, there are a lot of challenges with conventional weight reduction strategies.

Kucinskas and colleagues leveraged tirzepatide, certainly one of a brand new class of efficient anti-obesity drugs that focus on GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. The researchers sought to study whether or not or not tirzepatide would cut back obesity-associated breast cancer development.

This mouse study included 16 mice. The 9-week-old C57BL/6 mice have been fed a 40% high-fat eating regimen and housed in a heat atmosphere to induce weight problems. At 32 weeks of age, the mice with weight problems have been randomly assigned injections of tirzepatide or a placebo each different day for 16 weeks. Tumor volumes have been measured twice weekly.

The researchers discovered that the anti-obesity drug diminished physique weight and physique fats by roughly 20% in mice, much like the quantity of weight reduction achieved by ladies on this drug. They discovered this was primarily as a consequence of a lack of adipose mass, with a discount in adipose depot weights in comparison with controls.

The anti-obesity drug additionally diminished tumor quantity in comparison with the controls. At the tip of the review, the researchers discovered that tumor quantity was considerably correlated with physique weight, complete adipose mass and the quantity of fats saved within the liver.

“While these are very preliminary outcomes, they recommend that this new anti-obesity drug may have a useful affect on breast cancer outcomes,” Kucinskas mentioned.

Ongoing research are underway in collaboration with Dr. Steve Hursting’s lab on the University of North Carolina at Chapel Hill to separate the weight reduction from the tumor-specific results of tirzepatide.